IGIVNEX 10 G / 100 ML — DIN 02277921
IMMUNOGLOBULIN (HUMAN) : 10 G / 100 ML · GRIFOLS THERAPEUTICS LLC · SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is IGIVNEX?
IGIVNEX 10 G / 100 ML contains IMMUNOGLOBULIN (HUMAN) : 10 G / 100 ML. It is listed in the Health Canada Drug Product Database under DIN 02277921, held by GRIFOLS THERAPEUTICS LLC, supplied as SOLUTION for SUBCUTANEOUS ; INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 09-Oct-2012. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is IGIVNEX used for?
IGIVnex® (Immunoglobulin Intravenous [Human], 10%) Manufactured is indicated in Primary Immune Deficiency Syndromes (PID), Secondary Immune Deficiency Syndromes (SID), Neurological and/or Autoimmune Conditions. It is indicated as replacement therapy of primary humoral immunodeficiency states and for the reduction of septicemia and other infections, interstitial pneumonia and acute graft versus host disease in Allogeneic Bone Marrow Transplantation (BMT) patients.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Immunoglobulins, Normal Human, For Intravasc. Adm. cost around the world?
Immunoglobulins, Normal Human, For Intravasc. Adm. is listed on 7 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max); Czechia publishes a max producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Czechia | max producer price (ex-factory) | 15 | 93 | CZK███.██ |
| Austria | KVP (Kassenverkaufspreis) | 36 | 41 | EUR███.██ |
| Saudi Arabia | public | 11 | 22 | SAR███.██ |
| Bahrain | retail (max) | 5 | 16 | BHD███.██ |
| South Africa | single exit price | 8 | 11 | ZAR███.██ |
| Luxembourg | reimbursement | 10 | 10 | EUR███.██ |
| United Arab Emirates | public | 2 | 6 | AED███.██ |
199 pack listings across 87 brand entries and 6 price bases, refreshed 05 Sep 2026. Ranges span every Immunoglobulins, Normal Human, For Intravasc. Adm. pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Immunoglobulins, Normal Human, For Intravasc. Adm. in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
12 holders have a Canadian DIN containing Immunoglobulins, Normal Human, For Intravasc. Adm., across 25 DINs, of which 5 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| TAKEDA CANADA INC | 3 | 2 | GAMMAGARD LIQUID, GAMMAGARD S/D | Sourceable in Canada |
| GRIFOLS THERAPEUTICS LLC | 2 | 2 | GAMUNEX, IGIVNEX | Sourceable in Canada |
| CSL BEHRING CANADA INC | 3 | 1 | HIZENTRA, PRIVIGEN, SANDOGLOBULIN NF LIQUID | Sourceable in Canada |
| TALECRIS BIOTHERAPEUTICS INC | 4 | 0 | GAMIMUNE N 10% (IV), GAMIMUNE N 5% (IV), IMMUNE GLOBULIN INTRAVENOUS (HUMAN), 10%, IMMUNE GLOBULIN INTRAVENOUS (HUMAN), 5% | No marketed DIN |
| MEDIMMUNE LLC | 3 | 0 | RESPIGAM | No marketed DIN |
| OCTAPHARMA PHARMAZEUTIKA PRODUKTIONSGES M B H | 3 | 0 | OCTAGAM, OCTAGAM 5%, PANZYGA | No marketed DIN |
| INSTITUTO GRIFOLS S.A. | 2 | 0 | FLEBOGAMMA 10%, FLEBOGAMMA 5% | No marketed DIN |
| BAXALTA CANADA CORPORATION | 1 | 0 | GAMMAGARD S/D | No marketed DIN |
| BAXTER AG | 1 | 0 | IVEEGAM IMMUNO 5000MG (IV) | No marketed DIN |
| BAXTER CORPORATION | 1 | 0 | GAMMAGARD S/D (IV) | No marketed DIN |
| BAYER CORPORATION | 1 | 0 | IMMUNE GLOBULIN INTRAVENOUS (HUMAN) 5% | No marketed DIN |
| CUTTER MED & BIOL, DIVISION OF MILES CANADA LTD. | 1 | 0 | GAMIMUNE N INJ 5% (IV) | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 10 G / 100 ML |
|---|---|
| Dosage form | SOLUTION |
| Route | SUBCUTANEOUS ; INTRAVENOUS |
| Pack configuration (monograph) | null |
| Storage | null |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Substance and classification
| Active substance | Immunoglobulins, Normal Human, For Intravasc. Adm. |
|---|---|
| ATC code | J06BA02 |
| AHFS class | 80:04.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02277921 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2277921 |
| Brand name | IGIVNEX |
| Generic / active ingredient | IMMUNOGLOBULIN (HUMAN) : 10 G / 100 ML |
| Market authorization holder | GRIFOLS THERAPEUTICS LLC |
| Health Canada schedule | Schedule D |
| ATC code | J06BA02 |
| ATC anatomical main group | J — Anti-infectives for systemic use |
| ATC therapeutic subgroup | J06BA |
| Current status | MARKETED |
| Status date | 09-Oct-2012 |
| Original market date | 2006-05-24 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
5 of 25 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| GAMMAGARD LIQUID | 10 % | SOLUTION | TAKEDA CANADA INC | MARKETED | 02279444 |
| GAMMAGARD S/D | 5 G | SOLUTION ; POWDER FOR SOLUTION ; KIT | TAKEDA CANADA INC | MARKETED | 02231470 |
| GAMUNEX | 10 G / 100 ML | SOLUTION | GRIFOLS THERAPEUTICS LLC | MARKETED | 02247724 |
| PRIVIGEN | 10 % | SOLUTION | CSL BEHRING CANADA INC | MARKETED | 02304619 |
| FLEBOGAMMA 10% | 100 MG | SOLUTION | INSTITUTO GRIFOLS S.A. | APPROVED | 02467526 |
| FLEBOGAMMA 5% | 50 MG | SOLUTION | INSTITUTO GRIFOLS S.A. | APPROVED | 02467488 |
| GAMIMUNE N 10% (IV) | 100 MG | SOLUTION | TALECRIS BIOTHERAPEUTICS INC | CANCELLED POST MARKET | 02229695 |
| GAMIMUNE N 5% (IV) | 50 MG | SOLUTION | TALECRIS BIOTHERAPEUTICS INC | CANCELLED POST MARKET | 02178842 |
| GAMIMUNE N INJ 5% (IV) | 50 MG | LIQUID | CUTTER MED & BIOL, DIVISION OF MILES CANADA LTD. | CANCELLED POST MARKET | 00559261 |
| GAMMAGARD S/D | 10 G | SOLUTION ; KIT ; POWDER FOR SOLUTION | TAKEDA CANADA INC | DORMANT | 02231471 |
2 · Same class — other molecules in ATC J06BA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Immunoglobulins, Normal Human, For Extravasc. Adm | CUTAQUIG · CUVITRU · GAMASTAN · GAMASTAN S/D · +7 more | 25 | 11 | Yes |
| Immunoglobulins, Normal Human, For Intravasc. Adm. | FLEBOGAMMA 10% · FLEBOGAMMA 5% · GAMIMUNE N 10% (IV) · GAMIMUNE N 5% (IV) · +17 more | 25 | 5 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC J06B
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| J06BB | Anti-D (Rh) Immunoglobulin · Cytomegalovirus Immunoglobulin · Hepatitis B Immunoglobulin · Rabies Immunoglobulin · Tetanus Immunoglobulin · +1 more | 36 | 10 |
| J06BD | Casirivimab And Imdevimab · Nirsevimab · Palivizumab · Sipavibart · Sotrovimab · +1 more | 11 | 2 |
| J06B | Immunoglobulins | 1 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is IGIVNEX called?
The same molecule, Immunoglobulins, Normal Human, For Intravasc. Adm., is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| CUTAQUIG | Latin | Czechia |
| OCTAGAM | Latin | Czechia |
| KIOVIG | Latin | Bahrain, Czechia |
| PANZYGA | Latin | Czechia |
| CUVITRU | Latin | Bahrain, Czechia |
| Xembify | Latin | Czechia, Saudi Arabia |
| PRIVIGEN | Latin | Bahrain, Czechia |
| FLEBOGAMMA DIF | Latin | Czechia |
| GAMUNEX | Latin | Czechia |
| HIZENTRA | Latin | Czechia |
| HYQVIA | Latin | Czechia |
| IQYMUNE | Latin | Czechia |
| Octanorm | Latin | South Africa |
| IG VENA | Latin | Bahrain |
| Intratect | Latin | Saudi Arabia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.